Betulinic Acid-Doxorubicin-Drug Combination Induced Apoptotic Death via ROS Stimulation in a Relapsed AML MOLM-13 Cell Model.

B-cell lymphoma 2 family of proteins acute myeloid leukaemia apoptosis betulinic acid doxorubicin drug combination reactive oxygen species

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
14 Sep 2021
Historique:
received: 11 07 2021
revised: 27 08 2021
accepted: 07 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

In this study, cell death regulation and induction in AML cell line from a relapsed MLL-rearranged cell model (MOLM-13) was investigated with doxorubin (Dox) and betulinic acid (BetA), singly and in combination. CyQUANT Direct

Identifiants

pubmed: 34573088
pii: antiox10091456
doi: 10.3390/antiox10091456
pmc: PMC8471649
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cell Prolif. 2012 Dec;45(6):487-98
pubmed: 23030059
Mol Cells. 2012 May;33(5):517-24
pubmed: 22526391
Exp Cell Res. 2000 Jul 10;258(1):223-35
pubmed: 10912804
Cell Death Differ. 2006 Aug;13(8):1351-9
pubmed: 16763616
Cell Death Differ. 2010 Mar;17(3):381-97
pubmed: 20019744
Haematologica. 2012 Dec;97(12):1775
pubmed: 23204476
PLoS One. 2014 Aug 22;9(8):e105768
pubmed: 25148076
Cancer Lett. 2003 Feb 20;190(2):165-9
pubmed: 12565171
Biochem Pharmacol. 1999 Apr 1;57(7):727-41
pubmed: 10075079
Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):325-31
pubmed: 18495520
Biochem Pharmacol. 2015 Mar 1;94(1):1-11
pubmed: 25562745
Toxicol Lett. 2003 Jun 5;143(1):1-7
pubmed: 12697374
Genes Dev. 2011 Oct 1;25(19):1999-2010
pubmed: 21979913
J Clin Invest. 1999 Dec;104(12):1655-61
pubmed: 10606616
Sci Rep. 2017 Aug 14;7(1):8062
pubmed: 28808311
J Biol Chem. 2002 Nov 15;277(46):44317-26
pubmed: 12193597
Cell Death Differ. 2017 Aug;24(8):1348-1358
pubmed: 28234359
Biochem Pharmacol. 2010 Nov 15;80(10):1466-77
pubmed: 20709028
Mol Med Rep. 2018 Mar;17(3):4524-4530
pubmed: 29328378
Oncogene. 2007 Feb 26;26(9):1324-37
pubmed: 17322918
J Appl Physiol (1985). 2011 Oct;111(4):1190-8
pubmed: 21778418
Trends Cell Biol. 2015 Jun;25(6):354-63
pubmed: 25759175
Eur J Pharmacol. 2004 Sep 13;498(1-3):71-8
pubmed: 15363977
Oncogene. 2004 Oct 7;23(46):7611-20
pubmed: 15361826
Blood. 1993 Jun 1;81(11):3091-6
pubmed: 7684624
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18475-80
pubmed: 20937877
Acta Pharmacol Sin. 2012 Dec;33(12):1542-8
pubmed: 23064721
Integr Biol (Camb). 2011 May;3(5):548-59
pubmed: 21403972
Mol Carcinog. 2011 Oct;50(10):760-9
pubmed: 21751259
FEBS Lett. 2009 Dec 17;583(24):3966-73
pubmed: 19850042
Mol Pharmacol. 1994 Apr;45(4):649-56
pubmed: 8183243
Int J Mol Med. 2017 Dec;40(6):1669-1678
pubmed: 29039440
Acta Pharmacol Sin. 2013 May;34(5):625-35
pubmed: 23524572
Cancer Lett. 2007 Jun 18;251(1):132-45
pubmed: 17169485
Cancer Res. 2007 Dec 15;67(24):11848-58
pubmed: 18089815
Int Immunopharmacol. 2010 Aug;10(8):843-9
pubmed: 20430119
Cold Spring Harb Perspect Biol. 2013 Apr 01;5(4):a008714
pubmed: 23545417
Naunyn Schmiedebergs Arch Pharmacol. 2006 Oct;374(1):11-20
pubmed: 16964520
Front Cell Neurosci. 2018 Apr 25;12:95
pubmed: 29922130
J Invest Dermatol. 2000 May;114(5):935-40
pubmed: 10771474
Head Neck. 2003 Sep;25(9):732-40
pubmed: 12953308
Cancer Lett. 2002 Jan 10;175(1):17-25
pubmed: 11734332
Molecules. 2012 Mar 08;17(3):2939-54
pubmed: 22402764
Int J Mol Sci. 2008 Jun;9(6):1096-107
pubmed: 19325847
Autophagy. 2021 Jan;17(1):1-382
pubmed: 33634751
Cancer Res. 2007 Mar 15;67(6):2816-23
pubmed: 17363604
Int J Oncol. 2020 Jul;57(1):113-121
pubmed: 32377726
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Molecules. 2017 Feb 10;22(2):
pubmed: 28208611
J Exp Med. 2005 Dec 19;202(12):1691-701
pubmed: 16365148
Am J Cancer Res. 2012;2(2):214-21
pubmed: 22485198
PLoS One. 2018 Oct 29;13(10):e0206427
pubmed: 30372478
Drug Discov Today. 2009 Sep;14(17-18):885-90
pubmed: 19520182
Nat Med. 1995 Oct;1(10):1046-51
pubmed: 7489361
Cancer Res. 2001 May 15;61(10):4024-9
pubmed: 11358821
Cancer Res. 1997 Nov 1;57(21):4956-64
pubmed: 9354463
Oncotarget. 2016 Jul 12;7(28):44763-44778
pubmed: 27007056
Annu Rev Pharmacol Toxicol. 2007;47:143-83
pubmed: 17029566
Evid Based Complement Alternat Med. 2016;2016:8942730
pubmed: 27195016
J Biol Chem. 2004 Jun 11;279(24):25535-43
pubmed: 15054096
Leukemia. 2004 Aug;18(8):1406-12
pubmed: 15201849
Clin Cancer Res. 2003 Jul;9(7):2866-75
pubmed: 12855667
Blood. 2005 Aug 15;106(4):1154-63
pubmed: 15870183
Neoplasia. 2005 Feb;7(2):162-70
pubmed: 15802021
Toxicol Lett. 2005 Mar 15;155(3):343-51
pubmed: 15649617
Int J Oncol. 2016 Aug;49(2):753-62
pubmed: 27278553
Toxicology. 2016 Aug 31;370:41-48
pubmed: 27666003
Leuk Res. 2010 Feb;34(2):166-72
pubmed: 19520430
Biochim Biophys Acta. 2013 Dec;1833(12):3448-3459
pubmed: 23770045
J Immunol Methods. 2001 Aug 1;254(1-2):85-98
pubmed: 11406155
Oncogene. 2008 Oct 27;27(50):6398-406
pubmed: 18955968
Haematologica. 1995 Mar-Apr;80(2):98-102
pubmed: 7628759
Nature. 2012 Jan 11;481(7382):506-10
pubmed: 22237025
Cancer Cell. 2012 Apr 17;21(4):547-62
pubmed: 22516262
Free Radic Biol Med. 2017 Mar;104:144-164
pubmed: 28088622
Apoptosis. 2009 Feb;14(2):191-202
pubmed: 19115109

Auteurs

Milan Vu (M)

Department of Natural Sciences, Faculty of Science and Technology, Middlesex University, London NW4 4BT, UK.

Nick Kassouf (N)

Department of Natural Sciences, Faculty of Science and Technology, Middlesex University, London NW4 4BT, UK.

Sandra Appiah (S)

Department of Natural Sciences, Faculty of Science and Technology, Middlesex University, London NW4 4BT, UK.

Classifications MeSH